{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:55:54Z","timestamp":1790114154728,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In patients with differentiated thyroid cancer (DTC), tumor burden of persistent disease (PD) is a variable that could affect therapy efficiency. Our aim was to assess its correlation with the 2015 American Thyroid Association (ATA) risk-stratification system, and its impact on response to initial therapy and outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included 618 consecutive DTC patients referred for postoperative radioiodine (RAI) treatment. Patients were risk-stratified using the 2015 ATA guidelines according to postoperative data, before RAI treatment. Tumor burden of PD was classified into three categories, i.e. very small-, small- and large-volume PD. Very small-volume PD was defined by the presence of abnormal foci on post-RAI scintigraphy with SPECT\/CT or<jats:sup>18<\/jats:sup>FDG PET\/CT without identifiable lesions on anatomic imaging. Small- and large-volume PD were defined by lesions with a largest size &lt;\u200910 or\u2009\u2265\u200910\u2009mm respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PD was evidenced in 107 patients (17%). Mean follow-up for patients with PD was 7\u2009\u00b1\u20093\u2009years. The percentage of large-volume PD increased with the ATA risk (18, 56 and 89% in low-, intermediate- and high-risk patients, respectively,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). There was a significant trend for a decrease in excellent response rate from the very small-, small- to large-volume PD groups at 9\u201312\u2009months after initial therapy (71, 20 and 7%, respectively;<jats:italic>p<\/jats:italic>\u2009=\u20090.01) and at last follow-up visit (75, 28 and 16%, respectively;<jats:italic>p<\/jats:italic>\u2009=\u20090.04). On multivariate analysis, age\u2009\u2265\u200945\u2009years, distant and\/or thyroid bed disease, small-volume or large-volume tumor burden and<jats:sup>18<\/jats:sup>FDG-positive PD were independent risk factors for indeterminate or incomplete response at last follow-up visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The tumor burden of PD correlates with the ATA risk-stratification, affects the response to initial therapy and is an independent predictor of residual disease after a mean 7-yr follow-up. This variable might be taken into account in addition to the postoperative ATA risk-stratification to refine outcome prognostication after initial treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-07269-3","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T18:04:05Z","timestamp":1597428245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5181-8182","authenticated-orcid":false,"given":"Renaud","family":"Ciappuccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Heutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Lasne-Cardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Saguet-Rysanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Le H\u00e9naff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Vaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Babin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"issue":"1","key":"7269_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"issue":"8","key":"7269_CR2","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7269_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498\u2013505.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7269_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.humpath.2006.08.001","volume":"38","author":"JJ Michels","year":"2007","unstructured":"Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007;38(2):212\u20139.","journal-title":"Hum Pathol"},{"key":"7269_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2017.12.027","volume":"92","author":"C de la Fouchardiere","year":"2018","unstructured":"de la Fouchardiere C, Decaussin-Petrucci M, Berthiller J, Descotes F, Lopez J, Lifante JC, Peix JL, Giraudet AL, Delahaye A, Masson S, Bournaud-Salinas C, Borson CF. Predictive factors of outcome in poorly differentiated thyroid carcinomas. Eur J Cancer. 2018;92:40\u20137.","journal-title":"Eur J Cancer"},{"issue":"6","key":"7269_CR6","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1210\/jc.2016-2785","volume":"102","author":"M Melo","year":"2017","unstructured":"Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simoes M, Soares P, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simoes M, Soares P. TERT, BRAF, and NRAS in primary thyroid Cancer and metastatic disease. J Clin Endocrinol Metab. 2017;102(6):1898\u2013907.","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"7269_CR7","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1002\/cncr.30690","volume":"123","author":"MM Sabra","year":"2017","unstructured":"Sabra MM, Sherman EJ, Tuttle RM. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer. 2017;123(15):2955\u201364.","journal-title":"Cancer"},{"issue":"10","key":"7269_CR8","first-page":"1626","volume":"34","author":"D Casara","year":"1993","unstructured":"Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 1993;34(10):1626\u201331.","journal-title":"J Nucl Med"},{"issue":"2","key":"7269_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1530\/EJE-14-0192","volume":"171","author":"R Ciappuccini","year":"2014","unstructured":"Ciappuccini R, Hardouin J, Heutte N, Vaur D, Quak E, Rame JP, Blanchard D, de Raucourt D, Bardet S. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden. Eur J Endocrinol. 2014;171(2):247\u201352.","journal-title":"Eur J Endocrinol"},{"key":"7269_CR10","unstructured":"Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. 4th edition. Lyon: International Agency for Research on Cancer; 2017."},{"key":"7269_CR11","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th edition. Oxford: Wiley Blackwell; 2016.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"issue":"6","key":"7269_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1530\/EJE-11-0156","volume":"164","author":"R Ciappuccini","year":"2011","unstructured":"Ciappuccini R, Heutte N, Trzepla G, Rame JP, Vaur D, Aide N, Bardet S. Postablation (131) I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. Eur J Endocrinol. 2011;164(6):961\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"7269_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12020-013-0123-8","volume":"47","author":"E Robenshtok","year":"2014","unstructured":"Robenshtok E, Farooki A, Grewal RK, Tuttle RM. Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. Endocrine. 2014;47(1):266\u201372.","journal-title":"Endocrine"},{"issue":"3","key":"7269_CR14","first-page":"1020","volume":"102","author":"L Lamartina","year":"2017","unstructured":"Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travagli JP, Schlumberger M, Hartl DM, Leboulleux S. Surgery for neck recurrence of differentiated thyroid Cancer: outcomes and risk factors. J Clin Endocrinol Metab. 2017;102(3):1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"7269_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00259-009-1299-2","volume":"37","author":"D Schmidt","year":"2010","unstructured":"Schmidt D, Linke R, Uder M, Kuwert T. Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT\/CT at the first radioablation. Eur J Nucl Med Mol Imaging. 2010;37(4):699\u2013705.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7269_CR16","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1210\/jc.2008-2313","volume":"94","author":"N Aide","year":"2009","unstructured":"Aide N, Heutte N, Rame JP, Rousseau E, Loiseau C, Henry-Amar M, Bardet S. Clinical relevance of single-photon emission computed tomography\/computed tomography of the neck and thorax in postablation (131) I scintigraphy for thyroid cancer. J Clin Endocrinol Metab. 2009;94(6):2075\u201384.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"7269_CR17","doi-asserted-by":"publisher","first-page":"e0162482","DOI":"10.1371\/journal.pone.0162482","volume":"11","author":"R Ciappuccini","year":"2016","unstructured":"Ciappuccini R, Aide N, Blanchard D, Rame JP, de Raucourt D, Michels JJ, Babin E, Bardet S. Incremental value of a dedicated head and neck acquisition during 18F-FDG PET\/CT in patients with differentiated thyroid Cancer. PLoS One. 2016;11(9):e0162482.","journal-title":"PLoS One"},{"issue":"1","key":"7269_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13550-018-0461-x","volume":"8","author":"R Ciappuccini","year":"2018","unstructured":"Ciappuccini R, Desmonts C, Licaj I, Blanc-Fournier C, Bardet S, Aide N. Optimization of a dedicated protocol using a small-voxel PSF reconstruction for head-and-neck (18) FDG PET\/CT imaging in differentiated thyroid cancer. EJNMMI Res. 2018;8(1):104.","journal-title":"EJNMMI Res"},{"issue":"1","key":"7269_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1210\/jc.2014-1199","volume":"100","author":"S Bardet","year":"2015","unstructured":"Bardet S, Ciappuccini R, Quak E, Rame JP, Blanchard D, de Raucourt D, Babin E, Michels JJ, Vaur D, Heutte N. Prognostic value of microscopic lymph node involvement in patients with papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100(1):132\u201340.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07269-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07269-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07269-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:21:49Z","timestamp":1667780509000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07269-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7269"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07269-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"13 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments. Baclesse Cancer Centre has licensed from the French Commission for Data Protection and Liberties (CNIL, MR-004 ref. 2214228 v0). This study was approved by the institutional review board of Baclesse hospital and all subjects gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"765"}}